ResearcherNanjing UniversityActive in the last 2 years

Juan Du

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers: 0
Trials: 4 (principal investigator on 2)
Grants: 0
Labs led: 0
Collaborators: 1

Papers, trials and grants by year

2023: 2 trials · 2024: 2 trials

Trials 4

NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreati… Principal investigator NCT06494514 ↗
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic… Study chair NCT06662006 ↗
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer Principal investigator NCT06051851 ↗
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer Study chair NCT06389760 ↗

Closest collaborators

The 1 strongest of 1 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Min Tu · 1 shared trial, 2024 · strength 0.68
- Trial NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line… NCT06494514 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.